Out of Pocket Cost Communication in Multiple Sclerosis Patients
Pilot Feasibility Study of Out-of-Pocket Cost Communication and Supportive Financial Services for Reducing Financial Toxicity Among Multiple Sclerosis Patients
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- OOP Cost Communication and Optimization
Given to everyone in the trial
- Usual Care
What it measured
Main measures
Patient Satisfaction Questionnaire
Month 3
Quality of life (reported by participants)
Other measures (5)
Percentage of Patients Participating in Cost Conversations
Month 3
Minutes of Patient Engagement in Cost Conversations
Month 3
Patient Adherence to Cost Optimization Program
Month 3
Quality of life (reported by participants)Change in Utilization of Financial Supportive Services
Baseline, Month 3
Accuracy of OOP Cost Estimates
Month 3
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* known diagnosis of MS as documented in the electronic medical record by a neurologist based on clinical and imaging findings * a prescription for DMTs as medication * not enrolled in a clinical trial that covers the cost of DMT * have capacity to consent
Exclusion criteria
* plan to receive treatment elsewhere * concurrent diagnosis of primary cancers (except for non-melanoma skin cancer) * unable to read and speak English.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This is a prospective randomized controlled trial of a cohort of adult multiple sclerosis (MS) patients visiting an outpatient neurology clinic. Sixty participants will be randomly assigned to the intervention arm or a control arm and will be followed for three months.
Papers
Results
Patient-Specific Out-of-Pocket Cost Communication and Remote Financial Navigation in Patients with Multiple Sclerosis: A Randomized Controlled Feasibility Study.Mult Scler Relat Disord · 2022
Background
Owens GM. Economic burden of multiple sclerosis and the role of managed sare organizations in multiple sclerosis management. Am J Manag Care. 2016 Jun;22(6 Suppl):s151-8.Background
Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639-47. doi: 10.3111/13696998.2013.778268. Epub 2013 Mar 7.Background
Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009 Aug;122(8):741-6. doi: 10.1016/j.amjmed.2009.04.012. Epub 2009 Jun 6.Background
Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology. 2015 May 26;84(21):2185-92. doi: 10.1212/WNL.0000000000001608. Epub 2015 Apr 24.Background
Rumrill PD Jr, Roessler RT, McMahon BT, Hennessey ML, Neath J. Gender as a differential indicator of the employment discrimination experiences of Americans with multiple sclerosis. Work. 2007;29(4):303-11.Background
de Souza JA, Yap B, Ratain MJ, Daugherty C. User beware: we need more science and less art when measuring financial toxicity in oncology. J Clin Oncol. 2015 Apr 20;33(12):1414-5. doi: 10.1200/JCO.2014.59.4986. Epub 2015 Mar 2. No abstract available.Background
Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial Hardships Experienced by Cancer Survivors: A Systematic Review. J Natl Cancer Inst. 2016 Oct 20;109(2):djw205. doi: 10.1093/jnci/djw205. Print 2017 Feb.Background
de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, Daugherty CK. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014 Oct 15;120(20):3245-53. doi: 10.1002/cncr.28814. Epub 2014 Jun 20.Background
de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, Nicholas LH, O'Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 Feb 1;123(3):476-484. doi: 10.1002/cncr.30369. Epub 2016 Oct 7.
Loading reviews and guidelines…
History
Started
Mar 2020
Main results due
Dec 2021
Finished
Dec 2021